comprehensive -WSS

comprehensive

author：fashion 2025-09-14 14:46:14 - browse：688

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： ASCO: AstraZeneca says CAR

hotspot

WSS

PEPFAR is under serious threat — and so is global health

Long Covid needs a new name — and a new frame

HIV drugs protect against transmission, even in unprotected sex

See how much Covid

FDA proposes changes to key medical devices approval pathway

WATCH: Why do bright lights make us see spots?

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

BMI, flaws aside, is found to be useful estimate of body fat in youth

Moonlake's readout produced a cash windfall. Risks remain

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

State Dept. review finds Biden bears some blame for Afghanistan failures

Food makers tried to stack nutrition panel with preferred experts

The cancer drug shortage isn’t new — and neither are the solutions

New Covid vaccine is recommended for everyone 6 months or older

Hepatitis C has a cure — but many Americans still lack access to it

Diverse clinical trials: Why aren’t we there yet?

Wikipedia

How medical schools plan to diversify without affirmative action

With trial win, GSK could get blood cancer drug back on market

Ultragenyx gene therapy for rare liver ailment succeeds in late

ASCO: AstraZeneca says CAR

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

explore

entertainment

hotspot

focus